ESMO 2023 | Breast cancer at ESMO 2023: ADCs and MONARCH 3

Oleg Gluz, MD, Evangelical Hospital Bethesda, Moenchengladbach, Germany, provides an overview of his highlights in breast cancer presented at the European Society for Medical Oncology (ESMO) 2023 Congress. Novel developments in the management of HR-positive, HER2-negative breast cancer with chemoimmunotherapy or antibody-drug conjugates (ADCs) were discussed. Dr Gulz additionally comments on pembrolizumab and nivolumab in early breast cancer and findings from the MONARCH 3 trial (NCT02246621) of abemaciclib. This interview took place at the ESMO 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.